🇺🇸 Everolimus Tablets in United States

19 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 19

Most-reported reactions

1. Abdominal Pain — 3 reports (15.79%)
2. Renal Impairment — 3 reports (15.79%)
3. Acute Kidney Injury — 2 reports (10.53%)
4. Concomitant Disease Progression — 2 reports (10.53%)
5. Diarrhoea — 2 reports (10.53%)
6. Product Use Issue — 2 reports (10.53%)
7. Stomatitis — 2 reports (10.53%)
8. Abdominal Abscess — 1 report (5.26%)
9. Altered State Of Consciousness — 1 report (5.26%)
10. Angioedema — 1 report (5.26%)

Source database →

Frequently asked questions

Is Everolimus Tablets approved in United States?

Everolimus Tablets does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Everolimus Tablets in United States?

Shandong Suncadia Medicine Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.